Detecting cancer recurrence as early as possible is integral to preventing disease progression to later and deadlier stages of cancer. However, are we employing tools reliable enough to make this detection, or are the flaws in our current practices being overlooked? Written by Rayna Saldanha, Bryan Kaplan, Claire Liddy, and Kesavan Venkatesh.

It is widely accepted that the fight against cancer is non-linear, with cancer recurrence being a common occurrence even post various cancer therapies. However, the earlier the recurrence can be detected, the higher the patient’s chances of survival. This is because it provides patients with the opportunity to…

In recent years there have been multiple trends impacting how people receive medical care including practice methods such as Concierge Medicine and Direct Corporate Care, as well as the movement towards value-based care. Written by Victoria Chen, Charlie Almoney, Omar Aly, and Gwyn Alexander.

The healthcare system in the United States has long been centered on hospital care and private or group practice, all covered by both public (medicare, medicaid) and private health insurance. However, in recent years there have been multiple interesting trends that could have the potential to change the way healthcare is administered in the United States…

Developments in life-sciences are increasingly contributing to creating a food production industry that is less prone to wide-spread pathogen outbreaks among consumer communities.

Written by Alex Kernagis, Ronak Mahatme and Nina Tedeschi

Photo by Maxim Potkin on Unsplash

For years, the FDA has enforced environmental monitoring protocols for food manufacturers in order to prevent the spread of pathogens not only within facilities, but also within grocery stores and communities where produce is sold. Within these environmental monitoring programs, companies will swab areas of their facilities and send samples to a third-party lab or conduct in-house testing to determine the presence of different pathogens. Ultimately, the FDA…

Data collection is instrumental to business and healthcare growth but can be time-consuming and overwhelming. So how can AI be used to solve this issue and advance the biotech industry? Written by Michael Linguadoca.

AI in the Biotech Industry

Artificial intelligence (AI) has previously held the preconceived notion of being a futuristic and foreign idea, yet the reality is that it plays a fundamental role in advancing technology today. By the end of 2021, 80% of emerging technologies will have AI foundations. Applications of AI in biotech consist of different roles focused on data collection and analysis. …

With the bladder cancer market projected to grow in the upcoming years, the development of new immunotherapies like STING Agonists allow for a breakthrough in the fight against bladder cancer. Written by Omar Aly, Sarah Bortel, Jakob Heinz, and Andrés Melendez.

Bladder Cancer Overview

Bladder cancer is the most expensive cancer per the National Cancer Institute, being ranked first in lifetime treatment costs and is the sixth most frequently diagnosed cancer. Estimates indicate that by the year 2023, the United States bladder cancer market will be close to six billion dollars. In 2018, Datamonitor Healthcare estimated 546,400 incident cases of bladder cancer globally…

Drug development has historically been a long, expensive, and difficult process. How will the use of artificial intelligence impact the future of this industry? Written by Charlie Almoney, Morgan Kofsky, Jake Pearson, and Jenny Zwerling

In 2019, the total estimated cost to research and develop a novel prescription medicine was $2.6 billion per drug. This figure has increased from $800 million in 2003. Additionally, the rate of success of drugs in clinical trials is 12%, a decrease by half over the same time period1. While costs have risen, the success rate of drug development has been driven down, displaying a…

We know MRD detection is feasible and widely employed for hematological cancers… but what does the future hold for solid tumor MRD technologies? Written by Alex Kernagis, Rayna Saldanha, Claire Liddy and Bryan Kaplan.

A New Frontier

The niche space of minimal residual disease testing is quickly growing within the world of biotech due to great strides in sequencing and biopsy technology development over the last decade. Minimal residual disease (MRD) is a term used to describe detectable residual fragments of cancer in patients who have had cancer treatment with a curative intent such as surgery or chemotherapy. …

Description: JHU’s newest student-run healthcare and life-sciences consulting group

An Exciting New Chapter

Cobalt Consulting Group was founded in 2020 to bridge the rapidly budding business community with the prestigious biomedical atmosphere of Johns Hopkins!

Cobalt is entirely operated by students at Johns Hopkins University, helping to advise innovative companies within the thriving industries of life-sciences and healthcare — historically consulting companies and startups that have brought in more than $200 million in grants and total venture funding to date.

Nearly half of our team comes with experience from the JHU Biomedical Engineering Department, the top BME program in the…

Cobalt Consulting Group

The newest student-run healthcare and life-sciences consulting group at the Johns Hopkins University

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store